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Abstract 
Background. Cholera, an acute diarrheal disease caused by Vibrio cholerae (V. cholerae), is an endemic 
disease and a major public health problem in Iran. Antibiotic therapy can decrease duration of the disease, 
transmission of infection and contamination of the environment. Considering different pattern of V. cholerae 
antibiotic resistance around the world, the aim of the current systematic review and meta-analysis was to 
evaluate the prevalence of antibiotic resistance of V. cholerae in Iran. 
Methods. A systematic review of the literature was performed using related keywords in the electronic 
national and international databases including SID, Irandoc, Iran Medex and Magiran as well as PubMed, 
Scopus, Google Scholar and ISI web of knowledge. Up to July 31, 2018, 27 eligible papers were included 
in our meta-analysis based on the defined inclusion criteria.
Results. V. cholerae O1 was the most prevalent strain isolated in Iran and exhibited a high resistance rate 
against numerous antibiotics including chloramphenicol (33.6%), oxytetracycline (40.2%), trimethoprim/
sulphamethoxazole (86%), tetracycline (34.5%), furazolidone (69.8%), streptomycin (93.8%), polymyxin 
(80.7%), ampicillin (32.1%), nalidixic acid (88.9%), kanamycin (29%) and amoxicillin (30.5%).
Conclusion. According to the meta-analysis results, antibiotic therapy with ciprofloxacin, doxycycline, 
erythromycin, gentamicin, azithromycin, cefixime and cefepime could be effective for the treatment of severe 
cases of cholera in Iran.
Introduction
Vibrio cholerae (V. cholerae) is a curved 
Gram-negative bacillus which belongs 
to the family Vibrionaceae and was first 
isolated and described by Koch at the end 
of the 19th century (1). The bacterium is 
a causative agent for cholera, an acute 
intestinal infection that is transmitted 
by ingestion of contaminated water and 
food (2). In addition to V. cholerae, other 
important Vibrio species in the genus Vibrio 
include V. parahaemolyticus, V. harveyi, V. 
alginolyticus, V.vulnificus, V. anguillarum 
and V. fluvialis, which are isolated from fish, 
shrimp and lobster in aquatic environments 
and are pathogenic for humans (3). V. 
cholerae can also live in marine and estuarine 
environments and multiply freely in water 
for years (1-3). Therefore, the bacterium can 
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cause endemic, epidemic and even pandemic 
diseases, especially where sanitation situation 
is weak and there is no access to safe water 
(1-3). According to the latest World Health 
Organization (WHO) estimation, there are 
from 1.3 to 4.0 million new cases of cholera 
causing 21,000 to 143,000 deaths each year 
in the world (4). Among many serogroups 
of V. cholerae, based on O antigen, O1 and 
O139 strains of V. cholerae are responsible 
for cholera in humans by secreting an 
enterotoxin encoded by the ctx gene (5). 
These serogroups are also associated with 
seven widespread pandemics of cholera 
and still remain as a worldwide problem in 
both developed and developing countries, 
especially in Asia, Africa and Latin America 
(5). This severe diarrhoeal disease is also a 
public health problem in Iran and outbreaks 
occur annually among Iranian people (6). 
In Iran, cholera is endemic, especially in 
regions close to the borders, and V. cholerae 
O1 Ogawa and Inaba serogroups of El Tor 
biotype were reported to be responsible for 
recent outbreaks (1998–2011) in Iran along 
with changeable antibiotic-resistant patterns 
(6-8). V. cholerae infection severity can range 
from mild to moderate in endemic areas (90% 
of cases), and to severe and rapidly fatal 
diarrhea (10% of cases) (9). Early diagnosis 
along with oral rehydration salts (ORS) 
solution containing glucose, potassium 
chloride, sodium chloride and trisodium 
citrate are essential for the successful 
treatment of cholera accompanied by mild 
watery diarrhea (9). However, management 
of severe cholera with severe dehydration 
requires intravenous rehydration along with 
appropriate antimicrobial therapy in order 
to decrease the duration of the disease, the 
volume of rehydration fluids, the transmission 
of infection and the contamination of the 
environment through reducing V. cholerae 
excretion in stool (9). Previously, due to 
the low resistance rate of V. cholerae to 
commonly used antibiotics, determination of 
the antibiotic susceptibility of bacteria was 
not recommended (10). However, reports 
have shown that resistance rate of V. cholerae 
is increasing worldwide (11). There is no 
overall estimation of antibacterial resistance 
of V. cholerae in Iran. Hence, this systematic 
review and meta-analysis was undertaken 
to determine the pattern of antibacterial 
resistance of V. cholerae isolated from 
clinical samples in Iran.
Materials and Methods
Data sources and search methods
Up to July 31, 2018, we searched the 
literature with the purpose of identifying 
studies reporting the prevalence of antibiotic 
resistance of V. cholerae in Iran. Main 
searched databases were PubMed, Scopus, 
Google Scholar and ISI web of knowledge 
to find eligible published English-language 
papers, as well as Scientific Information 
Database (SID), Iranian Research Institute 
for Information Science and Technology 
(Irandoc), Iran Medex and Magiran for 
Persian-language papers. Three main MeSH 
terms used for database searching were 
“antibiotic resistance, V. cholerae, Iran”. 
We also reviewed references of the included 
articles to find any relevant studies.
Selection of studies
The search results were assessed by two 
reviewers independently after review of title, 
abstract and full text of articles in order to 
collect eligible studies using inclusion and 
exclusion criteria. Our inclusion criteria were: 
cross-sectional studies, articles published in 
Persian or English languages, and articles that 
evaluated antibiotic susceptibility patterns of 
V. cholerae collected from clinical samples 
in Iran. The reasons for our exclusions 
were: investigation of antibiotic resistance 
of Vibrio species other than V. cholerae, 
investigation of antibiotic resistance of V. 
cholerae in other countries, investigation of 
antibiotic resistance of V. cholerae collected 
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from environmental samples, investigation 
of simultaneous resistance to antibiotics, 
other study types except cross-sectional 
(e.g. reviews, letters and case report studies), 
abstract list of congresses and duplicates, 
and insufficient data. 
Data collection
We extracted data from included articles 
and categorized. As shown in Table 1, required 
extracted data were: first author’s name, year 
of the study, region of the study, type of 
sample, bacterial identification methods, 
number of isolated bacteria, methods used for 
evaluation of antibiotic resistance, and drug 
resistance of V. cholerae to various antibiotics. 
The PRISMA (Preferred Reporting Items 
for Systematic review and Meta-Analyses) 
statement was used to improve systematic 
reviews and meta-analyses in all sections of 
the materials and methods (12).
Analytical approach
To perform meta-analyses, we analyzed 
the data collected from included studies in 
the Comprehensive Meta-Analysis (CMA) 
software version 2.2 (Biostat, Englewood, 
NJ, USA). A fixed-effect model in low 
heterogeneity and random effect model 
in large heterogeneity were applied to 
calculate the pooled data on the prevalence 
of V. cholerae antibiotic resistance in Iran. 
V. cholerae antibiotic resistance rate in 
different cities of Iran was calculated and 
expressed as percentage and 95% confidence 
intervals (95% CIs).
Cochrane Q-test (p < 0.05 was considered 
statistically significant) and I-squared (I2) 
index as well as funnel plots were used to 
check the possibility of heterogeneity and 
publication bias, respectively.
Results
Results of the search
A total of 283 articles were collected 
from PubMed, Scopus, Google Scholar, ISI 
web of knowledge and Iranian databases. As 
shown in Figure 1, after reviewing the titles, 
abstracts and full texts of the articles, and 
removing duplicates, non-relevant studies, 
articles with insufficient data, reviews, letters 
and case reports, 27 relevant articles were 
Figure 1 - Flow diagram of the article selection process
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































285Drug resistance of V. cholerae in Iran
selected for the meta-analysis. The main 
characteristics of 27 included studies are 
indicated in Table 1.
Included studies
Of the 27 included studies in this review, 
antibiotic resistance of V. cholerae was 
reported from Tehran (n = 3), Alborz (n 
= 2), Khuzastan (n = 2), Kerman (n = 1), 
Kermanshah (n = 2), Kashan (n = 5), Sistan 
& Baluchastan (n = 6), Golestan (n = 2), 
Qom (n = 1), Hamadan (n = 2), Qazvin (n 
= 1), and Guilan (n = 1) provinces. Disk 
diffusion method, broth microdilution 
and E-test were the most commonly used 
techniques to assess the susceptibility of V. 
cholerae isolates. Samples were clinical, 
and microbiological techniques were used 
for bacterial identification. Additionally, 
V. cholerae O1 serogroup, Ogawa/Inaba 
serotype and El Tor biotype were the most 
frequent strains in the included studies. O1 
polyvalent and Ogawa/Inaba monospecific 
antisera were used to determine specific 
serogroups. Finally, funnel plot of the meta-
analysis was used to check the possibility 
of publication bias of included studies 
on antibiotic resistance of V. cholerae to 
each drug (Figure 3). In some antibiotic 
resistances, the distribution of studies was 
symmetrical in funnel plot and vice versa.
Characteristics of V. cholerae antibiotic 
resistance
In the present study, the prevalence of V. 
cholerae resistance to different antibiotics 
was evaluated. Reported antibiotics 
were chloramphenicol, ciprofloxacin, 
doxycycline, erythromycin, oxytetracycline, 
t r ime thop r im/ su lphame thoxazo l e , 
tetracycline, gentamicin, furazolidone, 
streptomycin, polymyxin B, ampicillin, 
azithromycin, nalidixic acid, cefixime, 
cefepime, kanamycin and amoxicillin. The 
highest and lowest resistance rates for each 
antibiotic in different provinces are listed 
in Table 2. 
The data presented in the current study 
indicated a low rate of V. cholerae resistance 
against ciprofloxacin (1.8%), doxycycline 
(7.2%), erythromycin (18.6%), gentamicin 
(2.8%), azithromycin (0.8%), cefixime 
(3.7%) and cefepime (1.3%) in Iran (Table 2). 
Additionally, the highest rate of V. cholerae 
resistance in Iran were observed against 
chloramphenicol (33.6%), oxytetracycline 
(40.2%), trimethoprim/sulphamethoxazole 
(86%), tetracycline (34.5%), furazolidone 
(69.8%), streptomycin (93.8%), polymyxin 
(80.7%), ampicillin (32.1%), nalidixic acid 
(88.9%), kanamycin (29%) and amoxicillin 
(30.5%) (Table 2).
Discussion
Insufficient access to safe water and 
food along with other factors including 
age and climatic factors (e.g. temperature 
and humidity), are the major risk factors 
for the incidence of cholera infection 
(17, 39). In Iran, in addition to the above 
mentioned risk factors, the arrival of 
Afghan and Pakistani immigrants from 
ungovernable border crossing in eastern 
provinces especially Sistan & Baluchastan 
plays another key role in the emergence of 
cholera epidemic in Iran (17). The present 
study showed that V. cholerae O1 was 
as the most important V. cholerae strain 
isolated from Iranian patients. Cholera is 
a self-limiting illness that is treatable with 
timely administration of fluids through oral 
route (4). However, in severely dehydrated 
patients, appropriate antibiotic therapy is 
needed (4). Reports have shown that the 
antibiotic resistance pattern of V. cholerae 
O1 has changed over the years and similar 
to global condition, spread of antibiotic 
resistance to commonly used antibiotics 
is increasing in Iran (13, 17). Therefore, 
due to increasing antimicrobial resistance, 
extensive antibiotic administration is not 
recommended (4). The most important 

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































287Drug resistance of V. cholerae in Iran
antibiotics used to reduce the symptoms 
of cholera are cell growth inhibitors 
(penicillin, ampicillin, and vancomycin), 
protein synthesis inhibitors (erythromycin, 
chloramphenicol, streptomycin, kanamycin, 
gentamicin, spectinomycin, tetracycline, 
doxycycline and linezolid), folic acid 
metabolism inhibitors (trimethoprim 
and sulfamethoxazole), DNA replication 
inhibitors (ciprofloxacin, nalidixic acid 
and norfloxacin) and inducers of cell 
lysis/cytotoxicity (polymyxin B) (40). 
Tetracyclines and quinolones antibiotics 
were extensively used against V. cholera 
but resistance is relatively common and has 
restricted their application in severe cases 
(40). In these cases, co-administration of 
doxycycline along with oral rehydration 
is recommended (40). In the present 
study, resistance high rates of V. cholerae 
against tested tetracyclines and quinolones 
antibiotics including oxytetracycline 
(40.2%), tetracycline (34.5%), furazolidone 
(69.8%) and nalidixic acid (88.9%) were 
found in Iran. However, resistance rates 
to ciprofloxacin (1.8%) and doxycycline 
(7.2%) were low (Table 2). Dengo-Baloi et 
al. reported that V. cholerae O1 resistance 
to tetracycline, doxycycline, ciprofloxacin 
and nalidixic acid were 50%, 56%, 0% 
and 100%, respectively, in Mozambique 
(41). Chomvarin et al. reported antibiotic 
susceptibility pattern of V. cholerae O1 in 
Thailand as follows: 23% to tetracycline, 
and 0% to ciprofloxacin (42). Additionally, 
in Ghana, resistance profiles were 0% to 
tetracycline, 98.4% to ciprofloxacin and 
100% to nalidixic acid (43). Erythromycin 
and furazolidone are used as alternatives 
to tetracyclines in children and pregnant 
women infected with cholera (44). 
However, according to the results of the 
current study, resistance to furazolidone is 
relatively common in Iran (69.8%) (Table 
2). Therefore, in young children, antibiotic 
therapy with erythromycin is recommended 
(40). Additionally, due to low macrolide 
resistance of V. cholera, these antibiotics are 
the drugs of choice for treatment of children 
and adults, especially azithromycin (45). 
In this study, V. cholerae resistance rates to 
erythromycin and azithromycin were 18.6% 
and 0.8%, respectively (Figure 2). Resistance 
rate of V. cholerae strains to macrolides 
in Iran was higher than in Mozambique 
(13% for azithromycin) and lower than 
in Thailand (71% for erythromycin) (41, 
42). Bacterial efflux pumps, spontaneous 
mutations, SXT elements and mobile 
integrons, and conjugative plasmids are the 
main mechanisms of antibiotic resistance 
in V. cholerae strains (40). Studies have 
suggested that the dominant antibiotic-
resistance mechanisms of V. cholera against 
tetracycline and ciprofloxacin are VcaM (a 
bacterial ATP-driven efflux pump) and other 
types of V. cholerae efflux pumps belonging 
to the proton-motive force (PMF) pump 
family including MFS (major facilitator 
superfamily) that confers resistance to 
chloramphenicol and nalidixic acid, and 
RND (resistance–nodulation–cell division) 
systems that confers resistance to polymyxin 
B and erythromycin (40). However, the 
studies included in this meta-analysis did not 
evaluate antibiotic-resistance mechanisms 
of V. cholera. This meta-analysis showed 
that V. cholerae resistance rates to β-lactam 
antibiotics and aminoglycosides were 
variable and a higher resistance rate to 
ampicillin (32.1%), amoxicillin (30.5%), 
streptomycin (93.8%) and kanamycin (29%) 
was found compared to other β-lactam 
antibiotics and aminoglycosides such as 
cefixime (3.7%), cefepime (1.3%) and 
gentamicin (2.8%). Resistance to ampicillin 
was reported to be 100%, 31% and 95.2% 
in Mozambique, Thailand and Ghana, 
respectively (41-43), whereas sensitivity to 
gentamicin was reported in Thailand and 
Ghana (42, 43). Chloramphenicol is also 
another protein synthesis inhibitor that is 
commonly used to treat cholera infection. 
Our study showed that V. cholerae resistance 
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to chloramphenicol was relatively high in 
Iran (33.6%). Mechanisms of antibiotic 
resistance were not evaluated in the included 
studies. However, based on other studies, 
spontaneous chromosomal mutations may be 
involved (40). Resistance to chloramphenicol 
in Iran was higher than in Ghana (0%) 
and lower than in Mozambique (89%) 
(41, 43). Finally, V. cholerae resistance 
to trimethoprim/sulphamethoxazole was 
also high in Iran (86%). The results were 
consistent with reports from Mozambique 
(75%), Thailand (54%) and Ghana (96.8%) 
(41-43). Among the included studies, Adabi 
et al. (13) showed that SXT elements and 
mobile integrons, which harbor resistance 
genes to trimethoprim/sulphamethoxazole, 
chloramphenicol and streptomycin, are 
frequently present in clinical V. cholerae 
O1 isolates of Iran. However, further 
investigations are needed to determine the 
exact mechanisms of resistance.
Conclusions
The present meta-analysis on the 
epidemiology of antibiotic resistance 
showed that the V. cholerae O1 strains 
isolated in Iran exhibited a high resistance 
rate against numerous antibiotics, including 
chloramphenicol ,  oxyte t racycl ine , 
t r ime thop r im/ su lphame thoxazo l e , 
tetracycline, furazolidone, streptomycin, 
polymyxin B, ampicillin, nalidixic acid, 
kanamycin and amoxicillin. Therefore, 
antibiotic therapy with ciprofloxacin, 
doxycycline, erythromycin, gentamicin, 
azithromycin, cefixime and cefepime 
could be more effective for severe cases 
of cholera in Iran. Exploring different 
mechanisms of antibiotic resistance and 
the dominant antibiotic-resistant elements 
as well as continuous monitoring of V. 
cholerae antibiotic resistance seems to be 
necessary to achieve a better control of 
cholera in Iran.
Riassunto
Revisione sistematica con metanalisi dell’epidemio-
logia dell’antibioticoresistenza di Vibrio cholerae 
in Iran
Premessa. Il colera, una malattia diarroica acuta 
infettiva provocata dal Vibrio cholerae, è endemico in 
Iran, dove rappresenta un importante problema di Sanità 
Pubblica. La terapia antibiotica è in grado di ridurre la 
durata della malattia, la trasmissione dell’infezione e 
la contaminazione dell’ambiente. Tenendo presenti i 
diversi profili di resistenza antibiotica del V. cholerae 
osservati a livello globale, lo scopo della presente 
revisione sistematica con metanalisi è stato quello di 
valutare la prevalenza delle antibioticoresistenze del V. 
cholerae in Iran.
Metodi. È stata effettuata una revisione sistematica 
della letteratura, usando parole chiave, nelle basi dati 
elettroniche nazionali (Irandoc, Iran Medex, Magiran) 
ed internazionali (PubMed, Scopus, Google Scholar 
ed ISI Web of Knowledge). A tutto il 31 Luglio 
2018, sulla base di ben definiti criteri di inclusione 
ed esclusione, sono stati recuperati per la metanalisi 
27 lavori.
Risultati. Il V. cholerae O1 è risultato il ceppo pre-
valente tra quelli isolati in Iran, ed ha esibito un elevato 
tasso di resistenza verso numerosi antibiotici, tra cui 
il cloramfenicolo (33,6%), l’ossitetraciclina (40,2%), 
il trimetoprim/sulfametossazolo (86%), la tetraciclina 
(34,5%), il furazolidone (69,8%), la streptomicina 
(93,8%), la polimixina (80,7%), l’ampicillina (32,1%), 
l’acido nalidixico (88,9%), la kanamicina (29%) e 
l’amoxicillina (30,5%).
Conclusioni. Sulla base dei risultati della metanalisi, 
l’antibioticoterapia con ciprofloxacina, doxiciclina, 
eritromicina, gentamicina, azitromicina, cefixime e ce-
fepime può risultare efficace per il trattamento dei casi 
gravi di colera in Iran.
References
1. Khazaei H-A, Rezaei N, Bagheri G-R, Moin 
A-A. A six-year study on Vibrio cholerae in 
southeastern Iran. Jpn J Infect Dis 2005; 58(1): 
8-10.
2. Tavana A. Cholera outbreaks in Iran and duration 
time of outbreaks. J Glob Infect Dis 2009; 1(1): 
75-6.
3. Hosseini H, Cheraghali AM, Yalfani R, Razavi-
lar V. Incidence of Vibrio spp. in shrimp caught 
off the south coast of Iran. Food Control 2004; 
15(3): 187-90.
289Drug resistance of V. cholerae in Iran
4. World Health Organization (WHO). Cholera-
Fact sheet-Updated December 2017. World 
Health Organization, 2017. Available on: http://
www.who.int/ mediacentre/factsheets/fs107/en 
[Last accessed: 2018, Aug 31].
5. Theron J, Cilliers J, Du Preez M, Brözel V, 
Venter S. Detection of toxigenic Vibrio cholerae 
from environmental water samples by an en-
richment broth cultivation–pit-stop semi-nested 
PCR procedure. J Appl Microbiol 2000; 89(3): 
539-46.
6. Bakhshi B, Boustanshenas M, Mahmoudi-
aznaveh A. Emergence of Vibrio cholerae O1 
classical biotype in 2012 in Iran. Lett Appl 
Microbiol 2014; 58(2): 145-9.
7. Pourshafie M, Bakhshi B, Ranjbar R, et al. Dis-
semination of a single Vibrio cholerae clone in 
cholera outbreaks during 2005 in Iran. J Med 
Microbiol 2007; 56(12): 1615-9.
8. Izadi S, Shakeri H, Roham P, Sheikhzadeh K. 
Cholera outbreak in southeast of Iran: routes of 
transmission in the situation of good primary 
health care services and poor individual hy-
gienic practices. Jpn J Infect Dis 2006; 59(3): 
174-8.
9. Leibovici-Weissman Ya, Neuberger A, Bitter-
man R, Sinclair D, Salam MA, Paul M. Antimi-
crobial drugs for treating cholera. The Cochrane 
Library, 2014.
10. Dalsgaard A, Forslund A, Serichantalergs O, 
Sandvang D. Distribution and content of class 1 
integrons in different Vibrio cholerae O-serotype 
strains isolated in Thailand. Antimicrob Agents 
Chemother 2000; 44(5): 1315-21.
11. Garg P, Chakraborty S, Basu I, et al. Expanding 
multiple antibiotic resistance among clinical 
strains of Vibrio cholerae isolated from 1992–7 
in Calcutta, India. Epidemiol Infect 2000; 
124(3): 393-9.
12. Liberati A, Altman DG, Tetzlaff J, et al. The PRI-
SMA statement for reporting systematic reviews 
and meta-analyses of studies that evaluate health 
care interventions: explanation and elaboration. 
PLoS Med 2009; 6: e1000100.
13. Adabi M, Bakhshi B, Goudarzi H, Zahraei SM, 
Pourshafie MR. Distribution of class I integron 
and sulfamethoxazole trimethoprim constin in 
Vibrio cholerae isolated from patients in Iran. 
Microb Drug Resist 2009; 15(3): 179-84.
14. Rahbar M, Sabourian R, Saremi M, Abbasi 
M, Masoumi Asl H, Soroush M. Epidemioloic 
and drug Resistant Pattern of Vibrio Cholerae 
O1 Biotype EL Tor, Serotype Inaba during the 
summer of 2005 outbreak in Iran. J Ardabil Univ 
Med Sci 2007; 7(1): 41-5. [In Persian]
15. Hajia M, Saboorian R, Rahbar M. Antimicrobial 
Resistance Patterns of Isolated Vibrio cholerae 
Strains. Int J Enteric Pathog 2016; 4(1): 1-4.
16. Rahmani F, Fooladi A, Marashi S, Nourani M. 
Drug resistance in Vibrio cholerae strains iso-
lated from clinical specimens. Acta Microbiol 
Immunol Hung 2012; 59(1): 77-84.
17. Masoumi-Asl H, Gouya MM, Rahbar M, Sa-
bourian R. The epidemiology and antimicrobial 
resistance of cholera cases in Iran during 2013. 
Iran J Microbiol 2016; 8(4): 232-7.
18. Rahbar M, Zahraei M, Omidvarnia A, et al. Sur-
vey of epidemiology and bacteriology features 
of cholera in Iran. Asian Pac J Trop Dis 2010; 
3(1): 45-7.
19. Khany A, Farzami MR. Determination of tetra-
cycline resistance genes in Vibrio cholerae O1 
biotype El Tor serotype Inaba strains isolated 
from outbreaks occurred in Iran in 2013. Int J 
Med Res Health Sci 2016; 5(5): 121-6.
20. Rahnami Farzami M, Hajia M, Dolatyar A, 
Imani M, Saburian R, Rahbar M. Correlation 
of the Native Inaba Strain With the Dominant 
Isolated Strains Obtained From Outbreaks in 
2013 in Iran. Int J Enteric Pathog 2016; 4(4): 
1-5.
21. Bakhshi B, Pourshafie MR, Navabakbar F, et al. 
Comparison of distribution of virulence deter-
minants in clinical and environmental isolates 
of Vibrio cholera. Iran Biomed J 2008; 12(3): 
159-65.
22. Sedaghat M, Soltan S, poorshafie M, et al. The 
pathogenic hlyA gene and antibiotic resistance 
in 100 patients with cholera. J School Health 
and Health Research Institute 2006; 3: 53-60. 
[In Persian]
23. Marashi SMA, Esfahani BN, Tavakoli A, Mo-
ghim S, Pourshafie MR, Salehi M. Simultaneous 
detection of integrase and antibiotic resistance 
genes within SXT Constin in Vibrio cholerae 
O1 El Tor strains isolated from Iran using 
multiplex-PCR. Iran J Basic Med Sci 2012; 
15(3): 885-9.
24. Pourshafie M, Grimont F, Kohestani S, Grimont 
P. A molecular and phenotypic study of Vibrio 
cholerae in Iran. J Med Microbiol 2002; 51(5): 
392-8.
25. Sedaghat M, Rahimi F, Talebi M, Pourshafie M. 
Serotyping, Antibiotic Susceptibility Pattern and 
290 A. Yousefi et al.
Detection of hlyA Gene Among Cholera Patients 
in Iran. Jundishapur J Microbiol 2012; 6(1): 
20-3.
26. Barati H, Moradi G, Rasouli MA, Mohammadi 
P. Epidemiologic and drug resistance pattern 
of Vibrio cholerae O1 biotype El Tor, serotype 
Ogawa, in the 2011 cholera outbreak, in Alborz 
Province, Iran. Jundishapur J Microbiol 2015; 
8(11): e23477.
27. Ranjbar M, Rahmani E, Nooriamiri A, et al. 
High prevalence of multidrug-resistant strains 
of Vibrio cholerae, in a cholera outbreak in 
Tehran–Iran, during June–September 2008. 
Tropical Doctor 2010; 40(4): 214-6.
28. Afzali H, Momen-Heravi M, Razzaghi R. An-
tibiotic Resistance of Vibrio cholerae Isolates 
from Kashan, Iran. Int Arch Health Sci 2016; 
3(2): 67-71.
29. Afzali H, Taghavi Ardekani A, Rasa H. Evaluation 
of antibiotic sensitivity of Shigella, Salmonella, 
and Vibrio cholera in patients with acute diarrhea 
referred to reference laboratory of Kashan Uni-
versity of Medical Sciences from 2000 to 2001. 
KAUMS J (FEYZ) 2001; 5(3): 47-58.
30. Afzali H, Khorshidi A, Moravveji SA, Baghbani 
A. Antibiotic resistance pattern of Vibrio cho-
lerae strains isolated from the stool of cholerae 
patients in Kashan during 1998-2009. KAUMS 
J (FEYZ) 2012; 16(4): 346-52.
31. Tabatabaei SM, Khorashad AS. Antimicrobial 
Resistance Patterns of Vibrio cholera Strains 
Isolated From Afghan and Iranian Patients in 
Iran. Int J Infect 2015; 2(1): e22822.
32. Salimi-Khorashad A, Tabatabaee SM, Amira-
badi A, Roudbar-Mohamadi S. Vibrio cholerae 
and Changing of Microbial Resistance Patterns 
in Sistan and Balouchestan Province. Zahedan 
J Res Med Sci 2012; 14(8): 63-6.
33. Rezaie N, Bakhshi B, Najar-Peerayeh S. Di-
stribution of resistance genetic determinants 
among Vibrio cholerae isolates of 2012 and 2013 
outbreaks in IR Iran. Microb Pathog 2017; 104: 
12-6.
34. Ranjbar R, Sadeghy J, Moghadam MS, Bakhshi 
B. Multi-locus variable number tandem repeat 
analysis of Vibrio cholerae isolates from 2012 to 
2013 cholera outbreaks in Iran. Microb Pathog 
2016; 97: 84-8.
35. Niknejad F, Kabir MJ, Keshtkar A, et al. An-
tibiotic susceptibility pattern of Vibrio cholera 
isolated from rectal swabs of patients in Golestan 
Province 2005. Lab Sci J 2007; 2(1): 32-7. [In 
Persian]
36. Keramat F, Hashemi S, Mamani M, Ranjbar M, 
Erfani H. Survey of antibiogram tests in chole-
ra patients in the 2005 epidemic in Hamadan, 
Islamic Republic of Iran. Eastern Mediterranean 
Health J 2008; 14: 768-75.
37. Talebi taher M, asefzadeh M, ghasemi R, nouri 
R. A survey of cholera in Qazvin. J Med Sci 
Qazvin 1999; 11: 102-08. [In Persian]
38. Rahbar Taramsari M, Khosh Amooz H, Hoseini 
S, Badsar AR, Vanak Araghiyan A, Falah Karkan 
M. Antibiotic Resistance Pattern of Cholera 
Epidemy in Guilan Province. J Guilan Univ Med 
Sci 2011; 82: 24-30. [In Persian]
39. Khademi F, Yousefi-Avarvand A, Vaez H. 
Cholera Outbreak in Yemen: A Regional or a 
Global Health Crisis?, Int J Infect 2018; 5(2):e 
62345.
40. Kitaoka M, Miyata ST, Unterweger D, Pukatzki 
S. Antibiotic resistance mechanisms of Vibrio 
cholerae. J Med Microbiol 2011; 60(4): 397-
407.
41. Dengo-Baloi LC, Semá-Baltazar CA, Manhique 
LV, Chitio JE, Inguane DL, Langa JP. Antibiotics 
resistance in El Tor Vibrio cholerae O1 isola-
ted during cholera outbreaks in Mozambique 
from 2012 to 2015. PloS One 2017; 12(8): 
e0181496.
42. Chomvarin C, Johura F-T, Mannan SB, et al. 
Drug response and genetic properties of Vibrio 
cholerae associated with endemic cholera in 
north-eastern Thailand, 2003–2011. J Med Mi-
crobiol 2013; 62(4): 599-609.
43. Eibach D, Herrera-León S, Gil H, et al. Molecu-
lar epidemiology and antibiotic susceptibility of 
Vibrio cholerae associated with a large cholera 
outbreak in Ghana in 2014. PLoS Negl Trop Dis 
2016; 10(5): e0004751.
44. Carroll KC, Butel JS, Morse SA. Jawetz Mel-
nick & Adelbergs Medical Microbiology 27 E: 
McGraw Hill Professional; 2015.
45. Murray PR, Rosenthal KS, Pfaller MA. Me-
dical microbiology. Elsevier Health Sciences, 
2015.
Corresponding author: Dr. Farzad Khademi, Department of Microbiology, School of Medicine, Ardabil University 
of Medical Sciences, Ardabil, Iran
e-mail: k_farzad@yahoo.com and f.khademi@arums.ac.ir
